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Risk factors of end-stage renal disease and serum creatinine in a
community-based mass screening. This study evaluated risk factors for
end-stage renal disease (ESRD) and the prognostic significance of serum
creatinine levels in a community-based mass screening. We used the
registries of both community-based mass screening and chronic dialysis
programs. In 1983, a total of 107,192 subjects over 18 years of age (51,122
men and 56,070 women) participated in a mass-screening program in
Okinawa, Japan. Among them, serum creatinine data were available for
14,609 participants (5,613 men and 8,996 women). During 10 years of
follow-up, we identified 60 dialysis patients (29 men and 31 women)
among this group. Logistic regression analysis on the risk of ESRD was
performed to determine the significance of serum creatinine levels in
comparison with other clinical variables. The adjusted odds ratio (95%
confidence interval) was 5.31 (3.39 to 8.32) in men and 3.92 (2.88 to 5.34)
in women when compared to baseline serum creatinine levels of less than
1.0 mgldl in women and 1.2 mg/dl in men. Diastolic blood pressure was not
a significant predictor of ESRD. Results demonstrated the prognostic
significance of serum ereatinine in a community-based mass screening.
Gender difference in the incidence of ESRD was explained, at least partly,
by differences between clinical predictors and baseline serum ereatinine
levels.
The number of end-stage renal disease (ESRD) patients is
increasing worldwide; however, the reasons for this increase are
not clear [1, 2]. Because of the relatively low incidence of ESRD
in the general population, only a few studies have reported on
disease progression from the beginning of renal disease to ESRD
[3—61. Since most diseases are insidious at onset, a considerable
period of time may elapse before clinical diagnosis is made [7, 8],
and it is not uncommon for patients to be uremic when first seen.
Mass screening often detects renal disease leading to ESRD
before any other predictors are noted [9].
Although dipstick urinalysis and blood pressure readings are
routinely performed in community-based mass screening and have
proved useful as predictors for ESRD [9], the relationship be-
tween these risk factors and renal function is not known. Serum
creatinine and reciprocal serum creatinine reflect renal function
and are widely used to monitor the progression of renal failure
[10—121. Whether the association between risk factors and the
incidence of ESRD is due to the initiation of renal disease or to
the progression of pre-existing disease is not clear. Even though a
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gender difference in the incidence and prevalence of ESRD is
frequently observed in dialysis registries [1, 2, 13, 14], the reasons
for the difference are not clear. Generally, serum creatinine is
lower in women than in men. Although gender has been consid-
ered a significant risk factor for ESRD [9], it was not considered
when comparing the differences in serum creatinine levels of men
and women.
The present study examined the following issues in a commu-
nity-based mass screening: (1) whether serum creatinine is a
significant predictor of ESRD; (2) whether the association be-
tween blood pressure and the incidence of ESRD is due to the
initiation of renal disease or to the accelerated progression of
pre-existing disease; and (3) whether gender in correlation with
serum creatinine is an independent predictor of ESRD.
The incidence and relative risk of ESRD were determined using
the community-based registries for both mass screening and
chronic dialysis patients (ESRD). Results provided an epidemio-
logical evidence that was used to construct an efficient preventive
strategy for ESRD patients and that may encourage high-risk
patients to seek medical follow-up.
Methods
Study design
All individuals over 18 years of age who participated in the 1983
community-based mass health screening examinations in Oki-
nawa, Japan were eligible for this study. Okinawa encompasses a
number of subtropical islands and is located in the southern-most
part of Japan. The population is stable, around 1.1 million (1980
Census), and is ethnically homogeneous. Screening participants
were excluded from this study if the birth date, dipstick urinalysis
result, and serum creatinine level were not in the computer
database. Dialysis patients who had participated the 1983 mass
screening and who had since become dialysis patients during the
study period, up to March 31, 1994, were identified using the
Okinawa Dialysis Study (OKIDS) registry, which covers the same
geographic area. Their identities were further verified by review-
ing the medical records in the dialysis units. The cumulative
incidence of ESRD and the relative risk of ESRD based on serum
creatinine levels at the time of the mass screening were deter-
mined.
Mass-screening registry
A community-based mass screening health examination pro-
gram is conducted annually by the Okinawa General Health
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Serum
creatinine
mg/dl
Participants
number
(%)
SBP, mm Hg DBP, mm fig
mean mean
P(+)IH(+)
%
Men,
N = 5,613
<1.0
1.0—1.1
1.2—1.3
1.4—1.5
1.6+
476 (8.5)
2,913 (51.9)
1,820 (32.4)
295 (5.3)
109 (19)
132.2 19.3 80.8 10.9
130.9 18.4 81.0 I 1.1
131.7 17.8 82.0 10.9
137.5 20.5 84.4 11.6
142.6 23.2 85.7 12.6
(22.3)/(29.6)
(18.3)/(24.2)
(21.4)/(25.6)
(28.4)/(35.1)
(60.4)1(46.8)
Women,
N = 8,996
<1.0
1.0—1.1
1.2—1.3
1.4—1.5
1.6+
6,058 (67.4)
2,531 (28.1)
307 (3.4)
70(0.8)
30(0.3)
128.4 20.2 77.6 11.4
133.7 21.2 79.8 11.3
140.7 20.3 81.9 12.0
145.2 23.9 84.4 11.2
150.8 25.5 84.7 12.3
(15.0)/(59.1)
(20.6)/(65.8)
(38.3)/(68.0)
(51.4)/(57.1)
(71 .9)/(34.4)
+
Maintenance Association (OGHMA), under the direction of Dr.
Y. Ikemiya. Founded in 1972, OGHMA is a non-profit organiza-
tion whose work has been previously reported [9]. Annually,
doctors and nurses of the association visit residential areas and
places of business throughout Okinawa, including 55 villages,
towns, and cities and 864 individual and group workplaces such as
governmental offices, businesses, banks, and worker's unions. A
dipstick urinalysis (Ames dipstick) is performed, and a result of
more than I + is regarded as abnormal. Blood tests are done if
abnormal urinalysis, hypertension, or ally other problems are
found or upon the participant's request. Because the cost for the
blood test is not paid for by the public sector, it is not mandatory.
Serum creatinine is measured using the modified method of
Jaffe's reaction in an automated analyzer at OGHMA's labora-
tory. Hypertension is defined as a diastolic blood pressure of 90
mm Hg or higher, and systolic blood pressure of 140 mm Hg or
higher.
The computer-based database includes data acquired since
fiscal year 1983, April 1, 1983 through March 31, 1984, and
<1.0 6,058 (67.3) 7 476 (8.5) 0
1.0 1,813 (20.2) 5 1,227 (21.9) 0
1.1 718 (8.0) 2 1,686 (30.0) 3
1.2 222 (2.5) 3 1,260 (22.4) 2
1.3 85 (0.9) 2 560 (10.0) 2
1.4 46 (0.5) 1 231 (4.1) 3
1.5 24(0.3) 1 64(1.1) 1
1.6 11(0.1) 1 33 (0.6) 1
1.7 4 0 22(0.4) 4
1.8 1 0 12(0.2) 2
1.9 2 1 13(0.2) 2
2.0 12(0.1)
8,996(100)
8
31
29(0.5)
5,613(100)
9
29
includes the participant's name, birth date, sex, zip code, employ-
ment group code, residential code, and the results of clinical and
laboratory tests. From a total of 107,192 participants (51,122 men
and 56,070 women), serum creatinine data were available for
14,609 participants (5,613 men and 8,996 women; Table 1). The
data were organized according to the following baseline serum
creatinine levels for each gender: < 1.0 mg/dl, 1.0—1.1 mg/dl,
1.2—1.3 mg/dl, 1.4—1.5 mg/dl, and  1.6 mg/dl.
Dialysis registry
Since 1971, all chronic dialysis patients in Okinawa have been
registered in an independent program. The characteristics and
other epidemiological features of the patients enrolled in this
registry have been reported previously [2, 15, 16]. Only patients
with end-stage renal disease and those who have survived at least
one month on scheduled dialysis were evaluated for our study.
Statistical analysis
The unpaired t-test and the equivalent nonparametric test, the
Wilcoxon rank-sum test, were used to compare continuous vari-
ables, and Fisher's exact test was used to compare discrete
variables between the groups. The cumulative incidence was
calculated as the ratio of the number of dialysis patients to the
number of screenees at risk for ESRD. All relative risks of ESRD
have been adjusted for age, systolic blood pressure, diastolic blood
pressure, protcinuria, and hematuria using the SAS model [17]. In
each case, the reference category was a serum creatinine level of
less than 1.0 mg!dl, To determine the relative strength among the
risk factors we examined, multiple logistic analysis was performed
and included all variables in the registry by gender. The depen-
dent variable in this model was binary, that is, dialysis or non-
dialysis status at the end of the observation period. For all relative
risks, we calculated the 95% confidence interval. Data are ex-
pressed as mean SD.
Results
Screening registry
Table 1 shows the demographics of the clinical and laboratory
variables of the participants according to baseline serum creati-
nine levels. Those who had blood tests (N 14,609) had a higher
Table 1. Clinical and laboratory variables based on the baseline levels
of serum creatinine
Table 2. Number of participants and ESRD patients in each baseline
levels of serum creatinine at the mass screening
Serum
creatinine
mg/dl
Number of screenees (%)
Women Men
Total ESRD Total ESRD
P(+)/H(+) denotes positive rate of dipstick urinalysis for proteinuria
and hematuria.
Total
I
Ii
2.0
1.5
1.0
0.5
0.0
469 1,205 1,466 1,168 851 454 Men
425 1,120 1,930 2,310 1,989 1,222 Women
18—29 30—39 40—49 50—59 60—69 70—
Age, years
Fig. 1. Mean (SD) serum creatinine levels compared with age at the mass
screening. Symbols are: (•) men; (0) women. Figures represent number of
participants at the mass screening.
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incidence of proteinuria (18.5% vs. 3.0%) than those who did not
have blood tests (N = 92,583). The proportion of high systolic
blood pressure ( 140 mm Hg) was 33.0% in the former and
30.1% in the latter, and that of high diastolic blood pressure ( 90
mm Hg) was 23.1% and 19.9%, respectively.
Figure 1 shows the average (SD) serum creatinine level by age
and gender for participants in the mass screening. Although men
had higher serum creatinine levels than women in all age groups,
the mean serum creatinine level did not change with age for either
gender.
Table 2 shows the number of screenees and ESRD patients
grouped according to baseline serum creatinine levels by gender.
In women, 95,5% had serum creatinine levels of less than 1.2
mgldl. In men, 92.8% had serum creatinine levels of less than 1.4
mgldl. The total number of screenees who developed ESRD
during the study period was 60 (29 men and 31 women).
Figure 2 shows the relationship between the cumulative inci-
dence of ESRD and baseline serum creatinine levels for partici-
pants in the mass screening. Although the cumulative incidence of
ESRD increased linearly for both men and women, the incidence
of ESRD was higher in women than in men at every serum
creatinine level.
Figure 3 shows the adjusted relative risk of ESRD as compared
to baseline serum creatinine levels. The significant level was 1.2
mg/dl in women and 1.4 mgldl in men.
Figure 4 shows a significant logarithmic correlation between
baseline serum creatinine levels determined at the mass screening
and the number of months from the screening to dialysis (r =
0.643; P < 0.01). The calculated duration to dialysis was about 64
months in participants with serum creatinine levels of 2.0 mg/dl.
Table 3 shows the results of the logistic analysis. For each 0.2
mg/dl increment of serum creatinine, the risk of ESRD increased
by 5.31 in men and 3.92 in women when compared to those who
had serum creatinine levels of less than 1.0 mgldl in women and
1.2 mg/dl in men. However, the risk was less than that indicated by
the presence of proteinuria. Neither systolic nor diastolic blood
pressure were independent risk factors for ESRD. In women,
hematuria was not an independent risk factor for ESRD.
Discussion
The cumulative incidence of ESRD in participants with re-
ported serum creatinine levels was 440 per 100,000 participants;
this was four times higher than those who did not have a blood test
in the 1983 mass screening [9]. This is not surprising because they
had a higher incidence of abnormal urinalysis and hypertension
(Table 1). Although the number of ESRD patients is increasing
worldwide, the reasons for this increase are not clear [1, 2].
Because it is thought that early detection leads to a reduction in
the incidence of ESRD, health checks or mass screening are
increasingly performed. However, few studies have reported on
mass screening in correlation with ESRD [9, 18, 19].
There was a direct relationship between baseline serum creat-
mine levels and the cumulative incidence of ESRD (Fig. 2).
Among the 14,609 participants with reported serum creatinine
data, 41 (29 men and 12 women) had elevated serum creatinine
levels of more than 2.0 mgldl. The current status of these
participants includes 17 (41.5%) who are entered in the ESRD
program, 10 (24.4%) who have expired, and 14 (34.1%) who are
alive without dialysis.
Because blood pressure was measured on only one occasion,
the predictability of blood pressures as a risk factor for ESRD may
he underestimated [20]. Both blood pressures increased with
baseline serum creatinine levels (Table 1). Therefore, neither
systolic nor diastolic blood pressure readings were considered to
be independent risk factors for ESRD when renal function was
estimated using serum creatinine levels (Table 3). However,
lowering blood pressure was shown to preserve renal function [21,
22]. Angiotensin-converting enzyme inhibitor, which offers renal
protection [23, 24], has been widely used in Japan since 1983. A
reduction in blood pressure is commonly associated with a
decrease in proteinuria [251.
The Japanese are a population with a relatively high incidence
of stroke [26]. Proteinuria and renal dysfunction are significant
predictors of death [27]. Therefore, it is possible that premature
deaths occurred before reaching ESRD were not counted, espe-
cially in patients with hypertension.
L.
a)
0
(I)
LU
0
a)
C.)
a)
0
100,000
10,000
1,000
100
10
<1.0 1.0—1.1 1.2—1.3 1.4—1.5 1.6+
Serum creatinine, mg/dI
Fig. 2. Cumulative incidence of ESRD compared
with serum creatinine levels at the mass screening.
Symbols are: () men; (LI) women.
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Serum creatinine, mg/dl
Fig. 3. Adjusted relative risk of ESRD compared with baseline serum
creatinine levels at the mass screening. Relative risk was calculated with
adjustments for age, proteinuria, hematuria, systolic blood pressure, and
diastolic blood pressure. In each case, the reference category is a baseline
serum creatinine level less than 1.0 mg/dl (women) and 1.2 mgldl (men).
Bars represent a 95% confidence interval. Symbols are: (•) men; (0)
women.
Men showed a higher risk and developed ESRD earlier than
women, even after adjusting for age, abnormal urinalysis, and
blood pressure reading [9]. Such gender difference in disease
progression was also reported in more focused studies on renal
biopsies [28, 29], lupus nephritis [30], and autosomal dominant
polycystic kidney disease [31]. However, when serum creatinine
levels in the normal range were similar, men showed a lower
incidence of ESRD than women (Fig. 2). Because serum creati-
nine indicates renal function (GFR), men should have either a
higher GFR or larger muscle mass per body size than women.
Nephron mass does not change after birth and is related to body
size [32]. Men usually have larger muscle mass per body size than
women and should, therefore, have a higher serum creatinine.
Hyperfiltration, high GFR per nephron, is hypothesized as a cause
of glomerular sclerosis leading to ES RD. It is increasingly recog-
nized that non-immunological factors play an important role in
the disease progression and in renal graft loss [331. Short stature
has also been associated with a higher risk of diabetic glomeru-
lopathy [3I. Besides the differences in mean levels of baseline
serum creatinine, changes in the adjusted relative risk of ESRD
showed a similar pattern in both men and women (Fig. 3). The
precise mechanism underlying the gender difference in renal
disease progression remains to he determined [351. The effect of
other confounding variables such as smoking, obesity, or lifestyle
were not examined in this study.
We found that the non-referral rate was more than 50% in
those participants with obvious renal dysfunction (serum creati-
nine of 2.0 mg/dl). Information regarding the medical response
to positive urinalysis, high blood pressure, and high serum creat-
mine levels detected at the mass screening was limited. However,
after reviewing the case records of the dialysis patients, we
speculate that a large number of them were not treated or were
not followed regularly by a nephrologist. About 25% of our case
dialysis patients with diabetes mellitus were first diagnosed at the
mass screening, even though they had no other evidence of renal
dysfunction [8].
Duration to dialysis, months
Fig. 4. Relationship between serum creatinine level at the mass screening
and the duration in months from the mass screening to dialysis.
Odds ratio' (95% confidence interval)
Men Women
Age (vs. <40)
10 year increments
Proteinuria (vs. normal)
Hematuria (vs. normal)
Systolic blood pressure(vs. < 140 mm Hg),
10 mm Hg increments
Diastolic blood pressure
(vs. <70 mm Hg), 10
mm Hg increments
Serum creatinine
(vs. < 1.0 mgldl), 0.2
mgldl increments
066h (0.47—0.94)
9.59" (3.14—29.31)
4.81" (1.96—11.81)
1.12 (0.75—1.67)
1.33 (0.82—2.18)
5.31" (3.39—8.32)
0.77 (0.54—1.08)
3.99k' (1.69—9.4:t)
1.70 (0.77—3.76)
0.97 (0.69—1.36)
1.47 (0.95—2.29)
3.92" (2.88—5.34)
In summary, this study demonstrated epidemiological evidence
that knowledge of serum creatinine levels increases the predict-
ability for ESRD when measured in conjunction with dipstick
urinalysis and blood pressure readings in community-based mass
screening. The adjusted relative risk of ESRD increased signifi-
cantly when the serum creatinine was greater than 1.2 mgldl in
women and 1.4 mgldl in men. High blood pressure was not an
independent risk factor for ESRD when considered with serum
creatinine, probably from the increased death rate due to stroke
and heart attack. Further study is necessary to determine whether
information obtained during mass screening provides early iden-
tification of at risk candidates or prevents ESRD, Higher risk of
ESRD in men was associated with a slightly higher baseline serum
creatinine level. A strategy for medical supervision is warranted
for this important public health policy. In view of the present
findings, more attention should be paid to detect early signs of
renal disease.
0
a)>
a)
ci)
(I)
0
9
7
5
3
1
E
a)C
C
(ci
ci)0
E
ci)
C/)
12
10
8
6
4
2
0
0
<1.0 1.0—1.1 1.2—1.3 1.4—1.5 1.6+
0 0
0 60 120
Table 3. Results of the logistical analysis on the predictor of dialysis
over 10 years among participants of the mass screening in 1983 in
Okinawa, Japan
'Adjusted to other variables in this Table.
"Statistically significant.
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